The National Marrow Donor Program selected an abstract co-written by Auayporn Nademanee, M.D., professor in the Division of Hematology & Hematopoietic Cell Transplantation, as one of four best abstracts at its annual Council Meeting in Minneapolis.
Nademanee presented the abstract, “Adult Patients with Malignancies Transplanted with Plasma Depleted Cord Blood (PD CB) – A Retrospective Audited Analysis of 107 Patients,” at the meeting.
She co-wrote the abstract with Robert Chow, M.D., founder and global medical director for StemCyte, an international umbilical stem cell storage bank and therapeutics company, as well as other colleagues. The abstract described the safety and effectiveness of transplanting single or double plasma-depleted umbilical cord blood units into adult patients with blood cancer.
“Patients treated with plasma-depleted cord blood demonstrated excellent outcomes in terms of overall survival, transplant-related mortality, and the absence of complications such as graft-versus-host disease,” she said. “We believe that plasma-depleted cord blood will continue to be an effective treatment for patients with leukemia, lymphoma and other malignant indications.”